Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies

Journal of the American Board of Family Medicine

Volumn 20, Issue 1, 2007, Pages 72-80

  Elliott, William J ^a   Plauschinat, Craig A ^b   Skrepnek, Grant H ^c   Gause, Douglas ^b  

^a RUSH MEDICAL COLLEGE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; VALSARTAN;

ADULT; AGED; ARTICLE; DATA BASE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSISTANT; MONOTHERAPY; PATIENT COMPLIANCE; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; TREATMENT DURATION; UNITED STATES;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICAL AUDIT; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED STATES;

EID: 33846887001     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2007.01.060094     Document Type: Article

References (44)

1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
2. American Heart Association. Heart Disease and Stroke Statistics: 2006 Update. Dallas, TX: American Heart Association, 2005.
3. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL, and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60.
4. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension 2004;44:398-404.
5. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.
6. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
7. Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003;21:1055-76.
8. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2004;42:1206-52.
9. Carol JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160:31-7.
10. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002;24:1347-57.
11. Gregoire JP, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol 2002;55:728-35.
12. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9.
13. Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997;19:1263-85.
14. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341-6.
15. Julius S, Kjeldsen SE, Weber M, et al., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
16. Malacco E, Santonastaso M, Vari NA, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004;26:855-65.
17. Malacco E, Varì N, Capuano V, et al. for the Val-Syst Investigators. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Clin Ther 2003;25:2765-80.
18. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: Implications for health care costs. Clin Ther 1997;19:1446-57.
19. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-81.
20. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. CMAJ 1999;160:41-6.
21. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23:1999-2010.
22. Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002;16:439-44.
23. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002;18:649-56.
24. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75.
25. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967-75.
26. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
27. Esposti LD, Di Martino M, Saragoni S, et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens (Greenwich) 2004;6:76-84.
28. Elliott WJ. Compliance-and improving it-in hypertension. Manag Care 2003;12(8 Suppl):56-61.
29. Skrepnek GH. Cost-effectiveness analysis. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics. Third edition. Cincinnati, OH: Harvey Whitney Books, 2005.
30. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994;32:214-26.
31. The Top 300 Prescriptions for 2004 by Number of US Prescriptions Dispensed. Available at: www.rxlist.com/top200.htm. Accessed March 27, 2006.
32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83.
33. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
34. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993;46:1075-9.
35. Skrepnek GH. Regression methods in the empiric analysis of health care data. J Manag Care Pharm 2005;11:240-51.
36. Burke LE, Ockene IS, ed. Compliance in Health Care and Research. New York: Futura Publishing, 2001.
37. Cheung BM, Ong KL, Man YB, Lam KS, Lau CP. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens (Greenwich) 2006;8:93-8.
38. Xu KT, Moloney M, Phillips S. Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for the management of uncomplicated essential hypertension. Am J Manag Care 2003;9:529-36.
39. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003;9:424-9.
40. Wu SC, Liu CP, Chiang HT, Lin SL. Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients. Heart Vessels 2004;19:13-18.
41. Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr Hypertens Rep 2002;4:424-33.
42. Spence JD, Hurley TC, Spence JD. Actual practice in hypertension: Implications for persistence with and effectiveness of therapy. Curr Hypertens Rep 2001;3:481-7.
43. Elliott WJ. Compliance strategies. Curr Opin Nephrol Hypertens 1994;3:271-8.
44. Neutel JM, Smith DH. Improving patient compliance: A major goal in the management of hypertension. J Clin Hypertens (Greenwich) 2003;5:127-32.